 BridgeBio Pharma Inc NASDAQ: BBIO is trading higher Tuesday as the stock rebounds after falling on Monday. BridgeBio Pharma shares traded lower Monday after the company announced that its Phase 3 trial to treat symptomatic transthyretin amyloid cardiomyopathy did not achieve its primary endpoint. 